PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS
申请人:Bristol-Myers Squibb Company
公开号:EP3252049A1
公开(公告)日:2017-12-06
The present invention provides compounds of Formula (I):
or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
本发明提供了式 (I) 的化合物:
或其立体异构体、同系物或药学上可接受的盐,其中所有变量如本文所定义。这些化合物是选择性 ROCK 抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些化合物治疗心血管、平滑肌、肿瘤、神经病理、自身免疫、纤维化和/或炎症性疾病的方法。
A new synthesis of methyl α-acetolactate based on thiazolium chemistry and modelled on the enzymatic synthesis of α-acetolactate catalysed by acetolactate synthase
作者:David H. G. Crout、Edward R. Lee、David P. J. Pearson
DOI:10.1039/c39900000331
日期:——
Methylα-acetolactate [methyl 2-hydroxy-2-methyl-3-oxobutanoate (13)] has been synthesised via a series of adducts with benzothiazole in a manner analogous to the enzymatic reaction catalysed by acetolactatesynthase.